Amryt Pharma
Amryt Pharma, a biopharmaceutical company headquartered in Ireland (IE), is dedicated to developing innovative treatments for rare and complex diseases. Founded in 2015, Amryt has rapidly established itself in the industry, focusing on areas such as dermatology and metabolic disorders. The company’s flagship products, including AP101 for epidermolysis bullosa and AP103 for other dermatological conditions, are distinguished by their unique formulations and targeted delivery mechanisms. Amryt Pharma has achieved significant milestones, including successful product launches and strategic partnerships, positioning itself as a leader in the rare disease market. With a commitment to improving patient outcomes, Amryt continues to expand its global reach, making a meaningful impact in the lives of those affected by challenging health conditions.
DitchCarbon Score
How does Amryt Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amryt Pharma's score of 60 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amryt Pharma's reported carbon emissions
In 2023, Amryt Pharma reported total carbon emissions of approximately 974,000,000 kg CO2e, with significant contributions from Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions were about 29,906,000 kg CO2e, while Scope 2 emissions totalled approximately 591,000 kg CO2e. The majority of their emissions, approximately 949,619,000 kg CO2e, fell under Scope 3, which typically includes indirect emissions from the supply chain and product use. Comparatively, in 2022, Amryt Pharma's emissions were slightly lower, with total emissions of about 895,000,000 kg CO2e, comprising 29,715,000 kg CO2e from Scope 1, 822,000 kg CO2e from Scope 2, and 897,564,000 kg CO2e from Scope 3. This indicates a slight increase in total emissions year-on-year. Amryt Pharma has not disclosed specific reduction targets or initiatives as part of their climate commitments, nor have they engaged with the Science Based Targets initiative (SBTi) for formal reduction targets. The absence of documented reduction initiatives suggests a need for further development in their climate strategy. Overall, while Amryt Pharma has made strides in transparency regarding their emissions, the lack of defined reduction targets highlights an area for potential improvement in their sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 27,507,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 1,771,000 | 000,000 | 000,000 |
| Scope 3 | 815,059,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amryt Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
